X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Dishman Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs DISHMAN PHARMA - Comparison Results

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES DISHMAN PHARMA ALKEM LABORATORIES/
DISHMAN PHARMA
 
P/E (TTM) x - 25.1 - View Chart
P/BV x 7.4 3.3 221.2% View Chart
Dividend Yield % 0.6 0.7 88.1%  

Financials

 ALKEM LABORATORIES   DISHMAN PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
DISHMAN PHARMA
Mar-16
ALKEM LABORATORIES/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,589374 424.4%   
Low Rs1,232129 955.8%   
Sales per share (Unadj.) Rs417.5197.8 211.1%  
Earnings per share (Unadj.) Rs56.321.2 265.5%  
Cash flow per share (Unadj.) Rs64.734.7 186.4%  
Dividends per share (Unadj.) Rs12.702.00 635.0%  
Dividend yield (eoy) %0.90.8 113.3%  
Book value per share (Unadj.) Rs292.9179.9 162.8%  
Shares outstanding (eoy) m119.5780.69 148.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.41.3 265.6%   
Avg P/E ratio x25.111.9 211.1%  
P/CF ratio (eoy) x21.87.2 300.8%  
Price / Book Value ratio x4.81.4 344.2%  
Dividend payout %22.69.4 239.2%   
Avg Mkt Cap Rs m168,65320,306 830.6%   
No. of employees `000NA0.8 0.0%   
Total wages/salary Rs m9,1715,355 171.3%   
Avg. sales/employee Rs ThNM19,252.7-  
Avg. wages/employee Rs ThNM6,459.5-  
Avg. net profit/employee Rs ThNM2,064.1-  
INCOME DATA
Net Sales Rs m49,91515,961 312.7%  
Other income Rs m1,645265 619.9%   
Total revenues Rs m51,56116,226 317.8%   
Gross profit Rs m8,4824,103 206.7%  
Depreciation Rs m1,0061,091 92.2%   
Interest Rs m671944 71.0%   
Profit before tax Rs m8,4512,334 362.1%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,606624 257.5%   
Profit after tax Rs m6,7311,711 393.4%  
Gross profit margin %17.025.7 66.1%  
Effective tax rate %19.026.7 71.1%   
Net profit margin %13.510.7 125.8%  
BALANCE SHEET DATA
Current assets Rs m27,06211,018 245.6%   
Current liabilities Rs m15,3249,517 161.0%   
Net working cap to sales %23.59.4 250.1%  
Current ratio x1.81.2 152.5%  
Inventory Days Days67110 60.2%  
Debtors Days Days4135 118.5%  
Net fixed assets Rs m12,61016,304 77.3%   
Share capital Rs m239161 148.1%   
"Free" reserves Rs m34,49012,907 267.2%   
Net worth Rs m35,02714,516 241.3%   
Long term debt Rs m1,2124,189 28.9%   
Total assets Rs m54,38729,805 182.5%  
Interest coverage x13.63.5 391.9%   
Debt to equity ratio x00.3 12.0%  
Sales to assets ratio x0.90.5 171.4%   
Return on assets %13.68.9 152.8%  
Return on equity %19.211.8 163.0%  
Return on capital %24.917.5 141.8%  
Exports to sales %12.924.8 52.2%   
Imports to sales %3.13.7 82.6%   
Exports (fob) Rs m6,4613,956 163.3%   
Imports (cif) Rs m1,540596 258.3%   
Fx inflow Rs m6,5634,952 132.6%   
Fx outflow Rs m3,012697 432.2%   
Net fx Rs m3,5524,255 83.5%   
CASH FLOW
From Operations Rs m7,2592,786 260.5%  
From Investments Rs m1,864-1,529 -121.9%  
From Financial Activity Rs m-9,273-941 985.3%  
Net Cashflow Rs m-150316 -47.4%  

Share Holding

Indian Promoters % 66.9 61.4 109.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 3.7 894.6%  
FIIs % 0.0 12.7 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 22.1 -  
Shareholders   68,381 46,261 147.8%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   STRIDES SHASUN LTD  ELDER PHARMA  ALEMBIC LTD  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Feb 23, 2018 03:35 PM

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS